Topvision Eye Specialist Berhad, (0332) Fair Value & Analysis
Healthcare · MY · Market cap 48.0M MYR
Fair value as of: Jul 17, 2026
From 25 valuation models · updated 24 days ago
Share price −5.9% over the past month.
Below-average quality, and screening another 19% overvalued on our models.
What matters now
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
- Our model range runs from 0.1000 MYR (bear) to 0.1600 MYR (bull), base 0.1300 MYR. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 43/100 (below-average quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range 0.1500 MYR – 0.6806 MYR · fair‑value band 0.1000 MYR – 0.1600 MYR · the 0.1600 MYR price screens above the 0.1300 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Topvision Eye Specialist Berhad, (0332) currently trades at 0.1600 MYR, while our model-based Fair Value estimate is 0.1300 MYR, implying the stock looks roughly 18.8% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Topvision Eye Specialist Berhad, generated revenue of 45.5M MYR at a net margin of 2.8%. Revenue declined 2.7% year over year. It earns a return on equity of 2.9%. Net debt stands at 1.1M MYR. Fundamentals as of Jul 17, 2026
Our scenario range runs from 0.1000 MYR (bear case) to 0.1600 MYR (bull case); at 0.1600 MYR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -19%, 0332 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Dividend Discount (0.1900 MYR) versus Growth DCF (0.0400 MYR). Highest evidence: Growth DCF (80).
Notify me when 0332 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Topvision Eye Specialist Berhad, together with its subsidiaries, provides ophthalmology healthcare services in Malaysia.
Full company description
Topvision Eye Specialist Berhad, together with its subsidiaries, provides ophthalmology healthcare services in Malaysia. The company offers various eye care services for cataract, diabetic retinopathy, retinal detachment, glaucoma, age-related macular degeneration, pterygium, children's eye disorder, and other eye problems, including cornea ulcer, dry eyes, eyelid abscess, foreign body removal, subconjunctival hemorrhage, trauma, and viral conjunctivitis. It also engages in the provision of related medical consultancy services; marketing of eye supplements and health food products; retail sale of food and beverage; and import, export, and distribution of pharmaceuticals, medical devices and goods, cosmetics, and health supplements. The company was founded in 2010 and is headquartered in Shah Alam, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Topvision Eye Specialist Berhad, reported revenue of 45.8M MYR in FY2025 versus 39.5M MYR in FY2022, a compound +5.1%/yr. Reported net income was 2.0M MYR in FY2025, compounding −31.2%/yr from FY2022.
0332 screens 19% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Topvision Eye Specialist Berhad, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Topvision Eye Specialist Berhad, (0332) overvalued or undervalued?
What is the fair value of 0332?
What is the quality score of 0332?
What is the revenue of Topvision Eye Specialist Berhad, (0332)?
What is the net profit margin of 0332?
Does Topvision Eye Specialist Berhad, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Topvision Eye Specialist Berhad, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.